|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2600123290 |
|
最近更新日期: Date of Last Refreshed on: |
2026-04-23 16:49:34 |
|
注册时间: Date of Registration: |
2026-04-23 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
基于费曼学习法与情景模拟的双路径干预对初产妇分娩恐惧及控制感的影响研究 |
|
Public title: |
A Study on the Influence of Dual-Path Intervention Based on Feynman Learning Method and Scenario Simulation on Fear of Childbirth and Sense of Control in Primiparas |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
基于费曼学习法与情景模拟的双路径干预对初产妇分娩恐惧及控制感的影响研究 |
|
Scientific title: |
A Study on the Influence of Dual-Path Intervention Based on Feynman Learning Method and Scenario Simulation on Fear of Childbirth and Sense of Control in Primiparas |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
魏维维 |
研究负责人: |
魏维维 |
|
Applicant: |
Wei Weiwei |
Study leader: |
Wei Weiwei |
|
申请注册联系人电话: Applicant telephone: |
+86 23 6311 5100 |
研究负责人电话: Study leader's telephone: |
+86 23 6311 5100 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
42358326@qq.com |
研究负责人电子邮件: Study leader's E-mail: |
42358326@qq.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
重庆市渝中区袁家岗友谊路1号 |
研究负责人通讯地址: |
重庆市渝中区袁家岗友谊路1号 |
|
Applicant address: |
No. 1, Youyi Road, Yuanjiagang, Yuzhong District, Chongqing |
Study leader's address: |
No. 1, Youyi Road, Yuanjiagang, Yuzhong District, Chongqing |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
重庆医科大学附属第一医院 |
||
|
Applicant's institution: |
The First Affiliated Hospital of Chongqing Medical University |
||
|
研究负责人所在单位: |
重庆医科大学附属第一医院 |
||
|
Affiliation of the Leader: |
The First Affiliated Hospital of Chongqing Medical University |
||
|
是否获伦理委员会批准: |
是/Yes |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2026年科研伦审(2026-071-01) |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
重庆医科大学附属第一医院医学研究伦理审查委员会 |
||
|
Name of the ethic committee: |
Medical Research Ethics Review Committee of the First Affiliated Hospital of Chongqing Medical University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2026-03-17 00:00:00 |
||
|
伦理委员会联系人: |
张华 |
||
|
Contact Name of the ethic committee: |
Zhang Hua |
||
|
伦理委员会联系地址: |
重庆市渝中区袁家岗友谊路1号 |
||
|
Contact Address of the ethic committee: |
No. 1, Youyi Road, Yuanjiagang, Yuzhong District, Chongqing |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 23 8901 1876 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
重庆医科大学附属第一医院 |
||||||||||||||||||||||
|
Primary sponsor: |
The First Affiliated Hospital of Chongqing Medical University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
重庆市渝中区袁家岗友谊路1号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No. 1, Youyi Road, Yuanjiagang, Yuzhong District, Chongqing |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
重庆医科大学附属第一医院2025年度护理科研创新项目 |
||||||||||||||||||||||
|
Source(s) of funding: |
2025 Annual Nursing Research and Innovation Project of the First Affiliated Hospital of Chongqing Medical University |
||||||||||||||||||||||
|
Target disease: |
Fear of Childbirth |
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
通过护理干预措施改善分娩恐惧、降低剖宫产率、提升产妇分娩体验,实现“保障母婴安全、促进自然分娩”的公共卫生目标。 |
||||||||||||||||||||||
|
Objectives of Study: |
Improve the fear of childbirth, reduce the cesarean section rate, and enhance the maternal childbirth experience through nursing intervention measures, so as to achieve the public health goal of "ensuring maternal and infant safety and promoting natural childbirth". |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1. 单胎初产妇,孕32~37周,计划阴道分娩者; 2. 孕周通过末次月经或早期超声准确核实; 3. 年龄20~40岁,无阴道分娩禁忌证; 4. 自愿签署知情同意书; 5. 具备基本的阅读和理解能力,能够独立完成调查表格。 |
||||||||||||||||||||||
|
Inclusion criteria |
1. Nulliparous women with singleton pregnancy, at 32-37 weeks of gestation, planning for vaginal delivery; 2. Gestational age accurately confirmed by last menstrual period or early ultrasound; 3. Aged 20-40 years, without contraindications to vaginal delivery; 4. Voluntarily signing the informed consent form; 5. Having basic reading and comprehension abilities and being able to independently complete the survey forms. |
||||||||||||||||||||||
|
排除标准: |
1. 严重妊娠合并症(如子痫前期、妊娠期糖尿病血糖控制不佳); 2. 胎儿严重结构畸形; 3. 沟通障碍或无法配合随访; 4. 有精神类病史者; 5. 孕妇拒绝参加本研究课题。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Severe pregnancy complications (such as preeclampsia, poorly controlled blood glucose in gestational diabetes); 2. Severe structural fetal malformations; 3. Communication disorders or inability to cooperate with follow-up; 4. History of mental illness; 5. Pregnant women refusing to participate in this research project. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2026-03-19 00:00:00至 To 2028-03-01 00:00:00 |
征募观察对象时间: Recruiting time: |
从From 2026-04-30 00:00:00 至 To 2027-04-30 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
女性 |
Gender: |
Female |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
对符合纳入标准的初产妇按入组顺序赋予1~252的唯一编号,使用 SPSS 27.0统计软件生成随机分配序列,设置固定种子数,生成均匀分布随机数字并排序,根据排序秩次,1~84 号为双路径干预组,85~168号为情景模拟干预组,169~252号常规干预组。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
Primiparas who meet the inclusion criteria are assigned unique numbers from 1 to 252 in the order of enrollment. The SPSS 27.0 statistical software is used to generate a random allocation sequence, produce uniformly distributed random numbers and sort them. According to the sorted ranks, numbers 1 to 84 are assigned to the dual-path intervention group, numbers 85 to 168 to the scenario simulation intervention group, and numbers 169 to 252 to the conventional intervention group. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
未说明 |
|
Blinding: |
Not stated |
|
是否共享原始数据: IPD sharing |
Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
公开原始数据日期:2026.4.30至2027.4.30。数据公开方式:邮箱:42358326@qq.com |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
Date of public release of raw data: April 30, 2026 to April 30, 2027. Method of data release: Email: 42358326@qq.com |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
基于国家网络安全要求进行数据管理,使用病例记录表和基于互联网的EDC,进行数据采集和管理。 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Data management is carried out in accordance with national cybersecurity requirements, and data collection and management are performed using case record forms and internet-based EDC. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |